ZLAB — Zai Lab Ltd

Zai Lab Ltd (ZLAB) is a biotechnology company listed on NASDAQ. It is led by Ying Du Ph.D., based in Building B, Pudong, China, 201203, with about 1,784 employees. Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Latest reported ZLAB revenue for 2025-09-30 was $116.1M. Net income was -$36.0M. Revenue was up 5.6% from 2025-06-30 to 2025-09-30. ZLAB currently screens at market cap $2.02B.

Use this ZLAB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZLAB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZLAB SEC filings page. Lician reads the product cache first so this HTML stays unique to Zai Lab Ltd even when a live quote feed is slow.